Antibiotic teicoplanin tested for stubborn gut infection
NCT ID NCT04003818
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested the antibiotic teicoplanin (taken by mouth twice daily for 7 to 14 days) in 50 adults hospitalized with C. difficile infection causing diarrhea and colitis. The goal was to see if it could stop diarrhea and prevent it from coming back. The trial was terminated early, so the full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Teicoplanin (an antibiotic taken by mouth)
- What this could lead to
- If successful, this could show that teicoplanin is a safe and effective option for treating C. difficile diarrhea and colitis.
- What could go wrong
- The trial was terminated early with only 50 participants planned, so results are limited. It is a phase 4 study, meaning the drug is already approved, but its effectiveness for this specific use is still being explored.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
50 people
The number who actually took part.
- Started
-
May 2020
- Finished
-
Mar 2021
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria : * Signed Informed Consent. * Male or female no less than 18 years of age. * Inpatient with a diagnosis of mild-moderate or severe CDAD (first occurrence or first recurrence within 3 months) with: Diarrhea: a change in bowel habits with \> 3 liquid or unformed bowel movements (UBM) within 24 hours prior to enrollment, AND Positive C. difficile toxin test on a stool sample produced within 72 hours prior to enrollment. Exclusion criteria: * More than one previous episode of CDAD in the 3-month period prior to enrollment. * Evidence of life-threatening or fulminant CDAD. * Likelihood of death within 72 hours from any cause. * History of inflammatory colitides, chronic abdominal pain, or chronic diarrhea * Antimicrobial treatment active against CDAD administered for \> 24 hours except for metronidazole treatment failures (MTF). * Known hypersensitivity or contraindication to teicoplanin. * Pregnant or nursing females. * Unable or unwilling to comply with all protocol requirements. * Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Clostridium difficile infection-associated diarrhea and colitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
investigational site CHINA
China, China